Periodic fever syndromes are a group of conditions that cause repeated, unexplained fevers. These conditions are rare, but there are treatment options. Share on Pinterest Ground Picture/Shutterstock A ...
Periodic fever syndromes are inflammatory conditions that cause recurrent fevers. Doctors use treatment to manage symptoms, avoid complications, or, in some cases, attempt to cure the syndrome.
DUBLIN & CAMBRIDGE, England & BRISBANE, Australia--(BUSINESS WIRE)--Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, ...
Cryopyrin-associated autoinflammatory syndromes, also called cryopyrin-associated periodic syndromes, are a group of three diseases in which the protein called cryopyrin, or NLRP3, is defective. It is ...
The FDA has approved Ilaris (canakinumab, from Novartis), a fully human monoclonal antibody that selectively blocks interleukin-1 beta (IL-1 beta), for the treatment of patients ≥4 years of age with ...
DUBLIN & CAMBRIDGE, England & BRISBANE, Australia--(BUSINESS WIRE)--Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, ...
New criteria have been proposed to enable a rapid diagnosis of cryopyrin-associated periodic syndromes (CAPS) in children and adults. Will these diagnostic criteria advance the management of ...
The FDA grants three simultaneous approvals for the expanded use of Novartis' (NYSE:NVS) Ilaris (canakinumab), currently available for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), ...
Novartis announced that the Food and Drug Administration (FDA) have granted Ilaris (canakinumab) three Breakthrough Therapy Designations, to treat three types of rare Periodic Fever Syndromes (also ...
Regeneron to host conference call on Thursday morning, February 28, 2008 at 8:30 a.m. Eastern Time TARRYTOWN, N.Y.--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced it has received ...
It’s been a while since Novartis’ rare disease med Ilaris picked up a label-expansion boost, but now the Swiss drugmaker has scored three of them. The pharma giant won FDA go-aheads for the therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results